Literature DB >> 32115666

Cutaneous Vasculitis with Gut Involvement During Secukinumab Treatment for Psoriatic Arthritis.

Clara Chelli1, Jeffrey Loget, Clélia Vanhaecke, Anne Durlach, Laurence Gagneux-Lemoussu, Clothilde Soriano, Manuelle Viguier.   

Abstract

Entities:  

Keywords:  cutaneous leukocytoclastic vasculitis Crohn’s disease; psoriatic arthritis

Mesh：

Substances：

Year:  2020        PMID： 32115666      PMCID： PMC9128929          DOI： 10.2340/00015555-3435

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  14 in total

Review 1.  [Paradoxical cutaneous manifestations during anti-TNF-alpha therapy].

Authors:  M Viguier; P Richette; H Bachelez; D Wendling; F Aubin
Journal:  Ann Dermatol Venereol       Date:  2009-12-08       Impact factor: 0.777

2.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

3.  Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Authors:  Kim Papp; Alice B Gottlieb; Luigi Naldi; David Pariser; Vincent Ho; Kavitha Goyal; Steven Fakharzadeh; Marc Chevrier; Stephen Calabro; Wayne Langholff; Gerald Krueger
Journal:  J Drugs Dermatol       Date:  2015-07       Impact factor: 2.114

4.  Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.

Authors:  Lluís Puig
Journal:  Curr Probl Dermatol       Date:  2017-11-07

5.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Authors:  Arthur Kavanaugh; Philip Helliwell; Christopher T Ritchlin
Journal:  Rheumatol Ther       Date:  2016-02-29

6.  Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.

Authors:  Yuichi Teraki; Aya Takahashi; Yumiko Inoue; Saori Takamura
Journal:  Acta Derm Venereol       Date:  2018-04-16       Impact factor: 4.437

7.  Vasculitis associated with tumor necrosis factor-α inhibitors.

Authors:  Olayemi Sokumbi; David A Wetter; Ashima Makol; Kenneth J Warrington
Journal:  Mayo Clin Proc       Date:  2012-07-13       Impact factor: 7.616

8.  Cutaneous leucocytoclastic vasculitis during secukinumab treatment.

Authors:  Alessia Villani; Gaia DE Fata Salvatores; Paola Nappa; Matteo Megna; Gabriella Fabbrocini; Maddalena Napolitano
Journal:  Ital J Dermatol Venerol       Date:  2019-01-09

9.  Granuloma Annulare in the Setting of Secukinumab.

Authors:  Matthew L Clark; Courtney A Tobin; Angela Sutton; Tricia Ann Missall
Journal:  Case Rep Dermatol Med       Date:  2018-04-01

10.  Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.

Authors:  Philip J Mease; Arthur Kavanaugh; Andreas Reimold; Hasan Tahir; Jürgen Rech; Stephen Hall; Piet Geusens; Pascale Pellet; Evie Maria Delicha; Shephard Mpofu; Luminita Pricop
Journal:  RMD Open       Date:  2018-08-13
View more
  2 in total

1.  Cutaneous Vasculitis During Secukinumab Treatment.

Authors:  Camila da Silva Cendon Duran; Mittermayer Barreto Santiago
Journal:  Eur J Case Rep Intern Med       Date:  2020-07-28

Review 2.  Vasculitis induced by biological agents used in rheumatology practice: A systematic review.

Authors:  Camila da Silva Cendon Duran; Adriane Souza da Paz; Mittermayer Barreto Santiago
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.